Reports Q3 adjusted EBITDA C$4.35M vs. C$2.97M last year. “The increase from the prior period is mainly due to growth in our global medical cannabis business and higher quarterly revenue in our plant propagation business, partially offset by a decline in our consumer cannabis net revenue.” Consolidated adjusted gross margin before fair value adjustments was 50% in Q3 2024 compared 46% in the prior year quarter. Adjusted gross profit before FV adjustments was $32.4 million in Q3 2024 (vs $28.0 prior year quarter, an increase of 15.7%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACB:
- Options Volatility and Implied Earnings Moves Today, February 08, 2024
- Aurora Cannabis Announces Fiscal 2024 Third Quarter Results; Generates Record Adjusted EBITDA of $4.3 Million
- Aurora Cannabis Acquires MedReleaf Australia
- Rising High: Exclusive talk with drug manufacturer Optimi Health
- Aurora Cannabis’ Board approves plan to consolidate outstanding shares
